Pharmaceutical company Pharming Group NV (Euronext Amsterdam:PHARM) announced on Wednesday its (unaudited) net loss of EUR10.0m for the full year ended 31 December 2015.
This marks a significant improvement when compared to the loss of EUR21.8m in 2014, excluding the one-off licensing income of EUR16.0m in 2014.
Unaudited revenues from product sales of EUR8.6m was collected in 2015, up from EUR3.0m in 2014 mainly as a result of a full year's sales in the US.Total revenues dropped to EUR10.8m (including EUR2.2 m of license revenue) in 2015 from EUR21.2m (including EUR18.2m in license revenue) in 2014.
The company's operating result rose slightly to an unaudited loss of EUR12.8m from a loss of EUR13.1m in 2014 (excluding the one-off license income in 2014), in spite of a considerable increase in R&D activity in 2015.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva